Plus   Neg

Retrophin: Phase 3 FORT Study Fails To Meet Endpoints - Quick Facts

Retrophin, Inc. (RTRX), a biopharmaceutical company, said the Phase 3 Study evaluating fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration failed to meet primary endpoint, as well as secondary endpoint. Fosmetpantotenate was generally safe and well-tolerated in the study.

Retrophin said the company will discuss with study investigators to decide the next steps for the FORT Study, including the ongoing open-label extension of the study.

Retrophin said it remains focused on advancing two pivotal Phase 3 programs evaluating sparsentan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world. Humanscale Corp. recalled about 24,900 units of QuickStand Lite workstations for concerns of injury hazard. These include about 2,200 units sold in Canada. The recalled workstation's arm can break and cause the workstation to fall, posing a risk of injury. The company has already received 52 reports of the arm breaking, including 12 reports of minor injuries. Facebook has revealed more details on the structure of an independent "oversight board" that will make final decisions about what posts stay up or come down, even if the company disagrees. The new "Oversight Board" will govern appeals from both Facebook and its users.
Follow RTT